Plain-English translation of NCT07313527 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research focuses on a specific blood test (PCR for Aspergillus fumigatus) that doctors use to detect and monitor a serious fungal lung infection. The study wants to understand whether changes in this blood test during treatment can help predict whether the medication is working and whether patients will recover.
Right now, doctors use this blood test alongside other markers to diagnose fungal lung infections, but there is very little data showing whether the test results actually predict treatment success. This study aims to fill that gap so doctors can better understand what the test results really mean for their patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would not need to do anything new — the study uses blood tests and lung fluid samples that have already been collected as part of your medical care at the hospital. Researchers will review your medical records and test results from January 2017 to December 2024 to see how your test levels changed during treatment and whether those changes matched your recovery.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
France
Sponsor
University Hospital, Strasbourg, France
Enrollment target
~100 participants
Started
March 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
baptiste Hoellinger, MD
University Hospital, Strasbourg, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.